The 10 most recent market catalysts affecting $ZYME, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 17, 2026
Corporate Catalyst
Neutral
Impact 55
Wolfe Research Initiates Coverage On Zymeworks with Outperform Rating
Wolfe Research analyst Kalpit Patel initiated coverage on Zymeworks with an 'Outperform' rating. This event signals a positive endorsement from a reputable research firm, suggestin…
Sep 3, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Overweight on Zymeworks, Raises Price Target to $33
JP Morgan analyst Brian Cheng maintained an 'Overweight' rating on Zymeworks and raised the price target from $31 to $33. This action signals a positive outlook from a prominent fi…
Aug 26, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy on Zymeworks, Raises Price Target to $38
Citigroup analyst Yigal Nochomovitz has maintained a 'Buy' rating on Zymeworks and slightly increased the price target from $37 to $38. This action signals continued analyst confid…
Aug 26, 2026
Corporate Catalyst
Bullish
Impact 65
Zymeworks shares are trading higher after HC Wainwright & Co maintained its Buy rating on the stock and raised the price target from $51 to $55. Also, Citizens reiterated its Market Outperform rating and maintained a $32 price target.
This headline represents a positive corporate catalyst for Zymeworks. The maintained 'Buy' and 'Market Outperform' ratings, coupled with a price target increase from HC Wainwright …
Aug 26, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $55
HC Wainwright & Co. analyst Robert Burns has maintained a 'Buy' rating on Zymeworks and raised the price target from $51 to $55. This action signals continued analyst confidence in…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 55
B. Riley Securities Reiterates Buy on Zymeworks, Raises Price Target to $44
This 8-K filing discloses that B. Riley Securities analyst Mayank Mamtani has reaffirmed a 'Buy' rating on Zymeworks (ZYME) and raised the price target from $40 to $44. This is a p…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $40
Wells Fargo analyst Eva Fortea Verdejo maintained an 'Overweight' rating on Zymeworks and raised the price target from $37 to $40. This action signals continued confidence in the c…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $32
Truist Securities analyst Gregory Renza has maintained a 'Buy' rating on Zymeworks (ZYME) and slightly increased the price target from $31 to $32. This action signals continued ana…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 75
Zymeworks Q2 EPS $(0.62) Misses $(0.41) Estimate, Sales $4.590M Miss $18.011M Estimate
This headline represents a significant negative corporate catalyst for Zymeworks. The substantial miss on both EPS and sales estimates suggests that the company's financial perform…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $51
HC Wainwright & Co. analyst Robert Burns maintained a 'Buy' rating on Zymeworks and raised the price target from $46 to $51. This action signals increased analyst confidence in Zym…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.